Today, PhRMA announced Collaborative Actions to Reach Equity (CAREs) grant recipients in response to the 2023 call for proposals, “Improving Cancer Outcomes in Diverse Populations.” As part of PhRMA’s continuing commitment to build a more just and equitable health care system, last year’s CAREs grants went towards initiatives which will develop and test scalable and replicable community-driven approaches to close cancer disparities.
Recognizing that each community faces unique barriers, PhRMA established the Collaborative Actions to Reach Equity (CAREs) grant program in April 2020. The CAREs grant program aims to support community-centered solutions to address health inequities through community partnerships. With these awards, PhRMA has awarded a total of nearly $750,000 in CAREs grants to community-based projects to address inequities across a range of health care issues, such as: reducing disparities in the treatment of chronic disease, increasing access to COVID-19 vaccinations in underserved communities, and reducing social and economic barriers health care and medicines.
We are proud to support innovative projects to advance health equity in cancer. These community-led initiatives are part of PhRMA’s resolve to disrupt the cycle of cancer racial disparities.
Congratulations to the 2023 PhRMA CAREs Grantees:
ALABAMA| Improving Cancer Outcomes at Alabama HBCU Institutions
Celeste Reese Willis, MD, Medical Director of Doctor Celeste Cares, in collaboration HBCU CARES
The Statewide Alabama Cancer Registry reveals that Black adults in Alabama experience higher rates of cancer-related deaths as compared to White peers. Reaching Black communities in Alabama for cancer prevention and awareness requires collaboration with community-centered organizations and institutions. Alabama encompasses 10% of HBCUs in the country. With PhRMA grant funding, Doctor Celeste Cares will collaborate with HBCU CARES, a not-for-profit consortium of the 14 HBCUs in Alabama, to develop and deliver cancer screenings and wellness clinics (both in-person and virtually) among HBCU students, faculty and the surrounding community members in Alabama. This program aims to establish a replicable model for improving cancer health outcomes in states with HBCUs and similar minority-serving institutions.
"I am elated to receive a grant from PhRMA and to partner with HBCU CARES to further health preventative strategies across Alabama's Historically Black Colleges and Universities (HBCUs)," said Dr. Celeste Reese Willis.
"They say an ounce of prevention goes a long way. Our mission is to positively impact the lives of the students and faculty at Alabama's HBCUs. We also aim to extend our outreach to their families by providing screenings and education that can be shared from one family member to another." – Celeste Reese Willis, MD (pictured above)
CALIFORNIA | Improving Cancer Outcomes in Asian American, Native Hawaiian, and Pacific Islander (AANHPI) Communities
Lily Shen, Chief of Staff, Nhien Le, Community Engagement Manager, and Sofia Karimi, Program Manager, Asian & Pacific Islander American Health Forum
Since 2000, cancer has been reported as the leading cause of death among Asian American, Native Hawaiian, and Pacific Islander (AANHPI) communities – accounting for 27% of all deaths in AANHPI communities. Language barriers, cultural misperceptions, and social stigma surrounding cancer are barriers to improving cancer prevention and outcomes in AANHPI communities. With PhRMA grant funding, the Asian & Pacific Islander American Health Forum (APIAHF) will collaborate with community-based organizations and community members to develop and distribute culturally and linguistically relevant educational resources about cancer prevention in AANHPI communities in California. Through joint efforts with community-based organizations in California, APIAHF will create tailored campaigns to reach 1) health care workers in a variety of care settings and 2) hard-to-reach uninsured, refugee/immigrant/migrant, and limited English proficient AANHPIs. The program aims to demonstrate best practices to increase the reach of cancer prevention efforts through culturally and linguistically relevant methods.
“Cancer is the leading cause of death for Asian Americans, Native Hawaiians, and Pacific Islander populations. Our Partnership with PhRMA’s Collaborative Actions to Reach Equity program will provide culturally and linguistically relevant educational resources that will raise awareness to unmet needs and improve healthcare accessibility by addressing barriers faced by AANHPI populations. The relevant cancer educational resources are not only meaningful but greatly needed in our community.” – Lily Shen (pictured left); Nhien Le and Sofia Karimi, co-investigators are pictured central and right.
MASSACHUSETTS | Evaluating the Impact of Racial Color-Blindness among Referring Oncology Clinicians
Jennifer Kim, PhD, Research Assistant Professor, Tufts Center for the Study of Drug Development, and Keith Maddox, PhD, Professor, Tufts University (Boston, MA)
Communities of color across the United States (U.S.) are enrolled in oncology clinical trials at a rate that is staggeringly lower than their White peers. Emerging research suggests that racial bias among clinicians, who act as gatekeepers to clinical trials, may affect referral of racial minority patients into pivotal clinical trials. With PhRMA grant funding, researchers at Tufts University will investigate how racial bias in the form of racial colorblindness, the belief that race does not matter in how people are treated, impacts healthcare providers’ willingness to refer patients of color into oncology clinical trials in the U.S. The study findings are aimed at inspiring best practices to improve racial sensitivity and awareness of bias among health care providers, and ultimately to close racial disparities in oncology trial enrollment.
Gaps in knowledge and awareness of clinical trials among Americans have been a known factor that contributes to the lack of clinical trial participation, particularly among communities of color in the U.S. However, what largely remains unknown is how bias among clinical trial gatekeepers – those who manage and referral and enrollment process – can contribute to this gap. This project will be among the first to explore and quantify how racial bias among clinical trial stakeholders can impact the referral and enrollment of racial minorities into clinical trials.” – Jennifer Kim, PhD (pictured left); Kenneth Maddox, PhD, co-investigator is pictured right
NEW MEXICO | Breathe Easy Lung Cancer Screening
Tim Tokarski, ED, Executive Director, New Mexico Cancer Center Foundation, Barbara McAneny MD, CEO New Mexico Cancer Center, Robert Lin MD, Clinical Champion
According to the CDC, New Mexico ranks 43rd in high-risk screening with lung screening rates at 1.9% (4.5% national average) and even lower rates in Tribal populations. Centuries of marginalization of Native Americans and Indigenous communities have created significant challenges to equitable health care outcomes. With PhRMA grant funding, the New Mexico Cancer Center (NMCC) Foundation will collaborate with trusted members in the Navajo Nation / Pueblos, and other marginalized communities to remove barriers to effective lung cancer screening and treatment access. With CAREs grant funding, NMCC Foundation will: 1) provide transportation to free lung cancer screening events in Albuquerque (no co-pay or insurance billing), 2) host health and wellness workshops during screening, 3) develop culturally appropriate materials to foster health care engagement and 4) navigate Tribal members and others with positive screening results to follow-up oncology / pulmonary care. The program aims to showcase best practices for cooperation among public, private, non-profit and Tribal nations to improve health outcomes in under-resourced communities.
“Community trust is a foundational element when engaging marginalized communities. As a multi-campus community oncology center the New Mexico Cancer Center and the NMCC Foundation is uniquely positioned to develop the partnerships that can advance equitable outcomes.” – Tim Tokarski (pictured left); Barbara McAneny, MD and Robert Lin, MD co-investigators are pictured central and right
NORTH CAROLINA | Targeting Cancer in Black Populations through Mobile Health Initiatives
Jennifer Johnson Edwards, DNP, RN, WHNP, CNE, Interim Associate Dean, Fayetteville State University
One in 10 working age adults in Cumberland County, North Carolina do not have health insurance, and 16% of the population has a household income below the Federal Poverty Line. With PhRMA grant funding, Fayetteville State University will use a mobile health care clinic to deliver education and cancer screening materials using a National Cancer Institute-validated, evidence-based approach. Fayetteville State University will also work with faith-based organizations, local barber and beauty shops, the local Health Department, and other established community partners to increase the reach and effectiveness of the program in the Cumberland County. The program aims to glean best practices around implementation of an evidence-based approach to increase cancer screenings using mobile health care.
“Research has shown that barriers exist in cancer prevention in the Black population. A culturally sensitive cancer prevention program may offer significant impact on cancer related knowledge and health seeking behaviors, thus improving health outcomes of this group.” – Jennifer Johnson Edwards, DNP, RN, WHNP, CNE
PhRMA is committed to doing its part to address the many interwoven factors that allow health inequities to persist. To that end, we believe addressing inequities effectively requires connecting with and learning from affected communities directly.
The PhRMA CAREs grant program will continue to support innovative solutions to make progress toward solutions to address inequities.
Follow our progress at https://phrma.org/en/Equity
Lori M. Reilly, Esq.
Lori M. Reilly is chief operating officer at PhRMA, providing executive level management, leadership and strategic direction for the organization. In this role, Reilly oversees PhRMA’s advocacy activities, including its federal, state and international government affairs and alliance development work. Reilly provides strategic leadership and works across PhRMA to develop and advocate for practical policy solutions that will lower costs for patients.
Reilly, named by the Washingtonian as one of the 250 most influential people in D.C., has a long record of working with members of Congress on a bipartisan basis and collaborating with stakeholders across the health care industry. Reilly is a frequent presenter on industry-related issues, including testifying before Congress on multiple occasions.
Reilly has over two decades of experience at PhRMA; prior to her current role, Reilly was the executive vice president of policy, research and membership at PhRMA, leading the development and implementation of legislative, regulatory and political strategies to advance policies that encourage patient access and medical innovation. She has also served as counsel at the U.S. House of Representatives Committee on Commerce and was Counsel to a member of the House Ways and Means Committee.
Reilly received a B.A. in political science from the University of Nebraska-Lincoln where she graduated with honors, and a J.D. from the University of Nebraska College of Law. She currently resides in Alexandria, Virginia with her husband and their four children.
Lori Reilly
https://www.linkedin.com/in/lorireillyphrma/
Chief Operating Officer
New study: HPV vaccination helps prevent cervical cancer deaths
America's cancer research progress is real and worth protecting
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
Advancing patient care: A look at new medicines approved in 2025
CAREs 2025: Supporting community-based solutions that improve access to medicines
New analysis finds 340B hospitals push patients toward costly care to boost profits
Price setting policies put cancer gains in jeopardy
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Guest Perspective: Prioritize Innovative Care
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
The importance of partnership: A conversation with Takeda
The future of oncology R&D lies in policymakers’ hands
Showcasing the promise of biopharma at ASCO 2024
Championing cancer equity: Our drive for healthier AANHPI communities
The impact of innovative medicines: A caregiver's perspective
Three things to know about antibody drug conjugates
The IRA’s pill penalty threatens the future of oncology R&D
New Report: 1,600 cancer treatments and vaccines in clinical development
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
Watch: New video series spotlights advances in biopharmaceutical science
Between hope and despair: Improving cancer outcomes
New report shows high-impact R&D happens after cancer medicines are first approved
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
ASCO 2023: Protecting our progress in the fight against cancer
Highlights from ASCO 2023
IRA Impacts: Cancer treatment research and development
State policymakers can protect American innovation and help Americans live longer, healthier lives
ICYMI: Cancer death rate continues to decline due to treatment advances
Novel medicines approved in 2022 offer increased treatment options for patients
Stories from the lab: Researchers discuss innovative treatments for cancers of the blood
ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research
Protecting treatment advances for breast cancer
Key takeaways from ASCO's annual meeting
ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free
Report: More than 500 medicines in development to treat disorders of the blood
4 things to know about biopharmaceutical efforts to fight cancer
New data show continued decline in death rates for cancer patients related to treatment advances
Recognizing National Immunization Awareness Month
Action needed to preserve the six protected classes
ICYMI: Cancer death rate continues decline due to advances in treatment
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Study finds biopharmaceutical innovation is responsible for 35% of the increase in life expectancy from 1990 to 2015
New report explores setbacks that bring future cancer success stories
Guest Post: Takeda seeks ‘new normal’ for cancer research during the COVID-19 pandemic
Cancer medicines cost twice as much at hospitals, study finds
Saving kids and dogs from shared cancers
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Spending on medicines grew less than one percent in 2017
Patients pay the price when hospitals mark up cancer medicines
A new era in cancer
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace
Protect your health: Important disaster preparedness tips for Harvey and Irma
Medicare Monday: New report highlights progress in fighting cancer with new physician-administered medicines
More than 240 immuno-oncology treatments in development to fight cancer
Medicines have significantly increased chances of cancer survival around the globe
ICYMI: Report highlights overall decrease in cancer death rates
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
The 20-year journey yielding a new weapon against cancer
Significant progress fighting cancer: Death rate has dropped 25 percent
"PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes"
Cancer
PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes
"PhRMA awards $250,000 to community-based projects to improve equitable cancer outcomes"